PUBLISHER: DelveInsight | PRODUCT CODE: 1126007
PUBLISHER: DelveInsight | PRODUCT CODE: 1126007
DelveInsight's 'Psoriatic Arthritis (PsA) - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of psoriatic arthritis (PsA) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Psoriatic arthritis (PsA) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted psoriatic arthritis (PsA) market size from 2019-2032 segmented by 7MM. The report also covers the current psoriatic arthritis (PsA) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Study period: 2019-2032.
Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis (PsA) resembles rheumatoid arthritis (RA) in symptoms characterized by joint inflammation. However, psoriatic arthritis (PsA) affects fewer joints than RA and does not produce the typical RA antibodies.
In 1956, Wright described arthritis associated with psoriasis. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of psoriatic arthritis (PsA) remained poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.
The etiology and pathogenesis of psoriatic arthritis (PsA) involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of psoriatic arthritis (PsA) patients have at least one first-degree relative with psoriasis or psoriatic arthritis (PsA). Genes associated with psoriatic arthritis (PsA) include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression, signaling, and T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma induces psoriatic skin lesions flares, known as the Koebner phenomenon. Evidence suggests that joint trauma may cause a flare of arthritis, referred to as the "internal" or "deep" Koebner phenomenon.
Psoriatic arthritis (PsA) shares some clinical features with other inflammatory arthritides, including RA, reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnosis. Unlike psoriatic arthritis (PsA), RA is symmetrical and generally spares the DIP joints. AS has an earlier onset age than psoriatic arthritis (PsA), and sacroiliac involvement is usually symmetric rather than asymmetric.
Psoriatic arthritis (PsA) may range from mild to severe, and treating it no matter the severity is crucial. If left untreated, psoriatic arthritis (PsA) can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating psoriatic arthritis (PsA) may also help reduce inflammation that could lead to other comorbidities. However, no cure for psoriatic arthritis (PsA) exists, so treatment goals are to slow disease progression, improve QoL, lessen pain, and preserve the range of motion. In most psoriatic arthritis (PsA) patients, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs, if a patient does not respond adequately.
It covers the details of conventional and current medical therapies and diagnoses available in the psoriatic arthritis (PsA) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
Psoriatic arthritis (PsA) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.
The disease epidemiology covered in the report provides historical and forecasted psoriatic arthritis (PsA) epidemiology segmented as the prevalent cases of psoriatic arthritis (PsA), diagnosed cases of psoriatic arthritis (PsA), gender-specific cases of psoriatic arthritis (PsA), age-specific cases of psoriatic arthritis (PsA) and severity-specific cases of psoriatic arthritis (PsA). The report includes the prevalent psoriatic arthritis (PsA) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides psoriatic arthritis (PsA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 15 million in 2021.
As per the estimates, the US had the highest total prevalent patient population of psoriatic arthritis (PsA) population in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.
The drug chapter segment of psoriatic arthritis (PsA) report encloses the detailed analysis of psoriatic arthritis (PsA) marketed drugs and late-stage (Phase III, Phase II/III, Phase II, and Phase I/II) pipeline drugs. It also helps understand psoriatic arthritis (PsA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The current standard of care lacks efficiency in treating psoriatic arthritis (PsA) that permanently cures PsA and demands need to develop more effective therapies for PsA. Although many effective PsA therapies, including csDMARDS, TNF inhibitors, various anti-IL inhibitors, and a variety of small molecule therapeutics, have been introduced over the last decade, spanning several different mechanisms of action. Still, many patients often do not respond to treatment due to various resistance symptoms. In addition to this, concerns over long-term safety profiles of csDMARDS and currently available biologics may limit their use, and patients can find treatments difficult due to regular blood monitoring, concerns of side effects, method of administration as well as the impact on metabolic risk, which in turn can lead to poor compliance and dissatisfaction.
Drug developers are gradually shifting their attention toward psoriatic arthritis (PsA) to meet the patient pool's current demands and counter the unmet needs of the therapeutic market.
Several companies are working robustly on many new therapies, such as bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB).
Bimekizumab (UCB Biopharma) is an investigational, humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently of IL-17A.
The safety and efficacy of bimekizumab are being evaluated across multiple disease states as part of a robust clinical program. The company is evaluating the drug in multiple Phase III clinical studies for PsA.
Tildrakizumab (Sun Pharmaceutical) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the US.
The drug is currently being evaluated in Phase III clinical studies in subjects with active psoriatic arthritis (PsA) with prior exposure to an anti-TNF agent(s) as well as in anti-TNF naive subjects with active psoriatic arthritis (PsA).
The company has filled marketing application for the manufacturing and marketing authorization of tildrakizumab for moderate-to-severe psoriasis and psoriatic arthritis (PsA) in Japan.
Psoriatic arthritis (PsA) market outlook builds a detailed comprehension of the historical, current, and forecasted psoriatic arthritis (PsA) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of psoriatic arthritis (PsA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
As per DelveInsight, psoriatic arthritis (PsA) market in 7MM is expected to change in the study period 2019-2032.
This section includes a glimpse of psoriatic arthritis (PsA) market in 7MM. In the 7MM, psoriatic arthritis (PsA) market size was approximately USD 9 billion in 2021.
This section provides the total psoriatic arthritis (PsA) market size. It also provides the market size of psoriatic arthritis (PsA) by systemic therapies and by-products in the United States.
The United States accounts for the highest market size of psoriatic arthritis (PsA) than the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
This section provides the total psoriatic arthritis (PsA) market size. It also provides the market size of psoriatic arthritis (PsA) by systemic therapies and by-products in Germany, France, Italy, Spain, and the United Kingdom.
This section provides the total psoriatic arthritis (PsA) market size. It also provides the market size of psoriatic arthritis (PsA) by systemic therapies and by-products in Japan.
This section focuses on the uptake rate of potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers psoriatic arthritis (PsA) market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stages. It also analyses psoriatic arthritis (PsA)'s key players in developing targeted therapeutics.
Major players include Sun Pharmaceuticals, Bristol Myers Squibb, Affibody AB, UCB Biopharma and others whose key products are expected to get launched in the US market by 20XX.
The report covers information on collaborations, acquisitions, mergers, licensing, and patent details for emerging psoriatic arthritis (PsA) therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in psoriatic arthritis (PsA) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or psoriatic arthritis (PsA) market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform a competitive and market intelligence analysis of psoriatic arthritis (PsA) market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.